Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8828412 | 0.83 | ALOX15 (0.59) | ALOX15ALDH1A1SMN1; SMN2FFAR1MEN1 | |
| SCHEMBL339492 | 0.82 | ALOX15 (0.81) | ALOX15ALDH1A1SMN1; SMN2FFAR1MEN1 | |
| SCHEMBL7929301 | 0.81 | MEN1 (0.58) | ALOX15ALDH1A1SMN1; SMN2MEN1MAPT | |
| SCHEMBL7400812 | 0.81 | ALOX15 (0.47) | GSK3BALOX15PTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11660630 | 0.81 | ALOX15 (0.57) | ALOX15ALDH1A1SMN1; SMN2FFAR1MEN1 | |
| SCHEMBL8314675 | 0.81 | ALOX15 (0.57) | GSK3BALOX15ALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL11658609 | 0.81 | ALOX15 (0.57) | GSK3BALOX15ALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL2009866 | 0.81 | GSK3B (0.64) | GSK3BPTPN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL5827387 | 0.80 | ALOX15 (0.65) | ALOX15PTPN1ALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL341847 | 0.80 | ALOX15 (0.65) | ALOX15ALDH1A1SMN1; SMN2FFAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | claimed |
| EP-4423251-A1 | SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118176293-A | SIRPalpha-deficient macrophages for the treatment of cancer | 佐治亚州立大学研究基金会公司 | 2024-06-11 | — | — | CN | claimed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | claimed |
| WO-2023076813-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-115803092-A | SIRP alpha deficient macrophages for the treatment of cancer | 乔治亚州立大学研究基金公司 | 2023-03-14 | — | — | CN | claimed |
| EP-4139003-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2021217038-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-28 | — | — | WO | claimed |
| US-9182385-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-8778620-B2 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2014-07-15 | — | — | US | claimed |
| WO-2010006291-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND TREATMENT | NODALITY, INC. (US) | 2010-01-14 | — | — | WO | claimed |
| US-20100009364-A1 | Methods for diagnosis, prognosis and methods of treatment | NODALITY, INC. (US) | 2010-01-14 | — | — | US | claimed |
| US-20090098594-A1 | Methods for diagnosis prognosis and methods of treatment | NODALITY, INC. (US) | 2009-04-16 | — | — | US | claimed |
| WO-2009025847-A2 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-7166696-B2 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-23 | — | — | US | claimed |
| US-20040265899-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | claimed |
| US-6787635-B2 | azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-07 | — | — | US | claimed |
| EP-1373167-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M Innovative Properties Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002081078-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173051-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | GSK3B 3602/4885ALOX15 2003/4885PTPN1 4530/4885 |
| US-20040265899-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | GSK3B 3602/4885ALOX15 2003/4885PTPN1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.